Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 32 entries
Sorted by: Best Match Show Resources per page
Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Guven DC, Sahin TK, Aksun MS, Taban H, Aktepe OH, Aksu NM, Akkaş M, Erman M, Kilickap S, Dizdar O, Aksoy S.
PMID: 32851486
Support Care Cancer. 2021 Apr;29(4):2029-2035. doi: 10.1007/s00520-020-05702-8. Epub 2020 Aug 26.

BACKGROUND: The emergency department (ED) is a crucial encounter point in cancer care. Yet, data on the causes of ED visits are limited in patients treated with immune checkpoint inhibitors (ICI). Therefore, we evaluated ED visits in patients treated...

Cite
Guven DC, Sahin TK, Aksun MS, et al. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Support Care Cancer. 2020;29(4):2029-2035doi: 10.1007/s00520-020-05702-8.
Guven, D. C., Sahin, T. K., Aksun, M. S., Taban, H., Aktepe, O. H., Aksu, N. M., Akkaş, M., Erman, M., Kilickap, S., Dizdar, O., & Aksoy, S. (2021). Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29(4), 2029-2035. https://doi.org/10.1007/s00520-020-05702-8
Guven, Deniz Can, et al. "Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. 29,4 (2021): 2029-2035. doi: https://doi.org/10.1007/s00520-020-05702-8
Guven DC, Sahin TK, Aksun MS, Taban H, Aktepe OH, Aksu NM, Akkaş M, Erman M, Kilickap S, Dizdar O, Aksoy S. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Support Care Cancer. 2021 Apr;29(4):2029-2035. doi: 10.1007/s00520-020-05702-8. Epub 2020 Aug 26. PMID: 32851486.
Copy Download .nbib Format: NLM
COVID-19 and immunomodulation treatment for women with reproductive failures.

Journal of reproductive immunology

Kwak-Kim J, Ota K, Sung N, Huang C, Alsubki L, Lee S, Han JW, Han A, Yang X, Saab W, Derbala Y, Wang WJ, He Q, Liao A, Takahashi T, Cavalcante MB, Barini R, Bao S, Fukui A, Lédée N, Coulam C.
PMID: 32603991
J Reprod Immunol. 2020 Sep;141:103168. doi: 10.1016/j.jri.2020.103168. Epub 2020 Jun 12.

COVID-19 pandemic is affecting various areas of health care, including human reproduction. Many women with reproductive failures, during the peri-implantation period and pregnancy, are on the immunotherapy using immune modulators and immunosuppressant due to underlying autoimmune diseases, cellular immune...

Cite
Kwak-Kim J, Ota K, Sung N, et al. COVID-19 and immunomodulation treatment for women with reproductive failures. J Reprod Immunol. 2020;141:103168doi: 10.1016/j.jri.2020.103168.
Kwak-Kim, J., Ota, K., Sung, N., Huang, C., Alsubki, L., Lee, S., Han, J. W., Han, A., Yang, X., Saab, W., Derbala, Y., Wang, W. J., He, Q., Liao, A., Takahashi, T., Cavalcante, M. B., Barini, R., Bao, S., Fukui, A., Lédée, N., & Coulam, C. (2020). COVID-19 and immunomodulation treatment for women with reproductive failures. Journal of reproductive immunology, 141103168. https://doi.org/10.1016/j.jri.2020.103168
Kwak-Kim, Joanne, et al. "COVID-19 and immunomodulation treatment for women with reproductive failures." Journal of reproductive immunology vol. 141 (2020): 103168. doi: https://doi.org/10.1016/j.jri.2020.103168
Kwak-Kim J, Ota K, Sung N, Huang C, Alsubki L, Lee S, Han JW, Han A, Yang X, Saab W, Derbala Y, Wang WJ, He Q, Liao A, Takahashi T, Cavalcante MB, Barini R, Bao S, Fukui A, Lédée N, Coulam C. COVID-19 and immunomodulation treatment for women with reproductive failures. J Reprod Immunol. 2020 Sep;141:103168. doi: 10.1016/j.jri.2020.103168. Epub 2020 Jun 12. PMID: 32603991; PMCID: PMC7291967.
Copy Download .nbib Format: NLM
Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report.

Journal for immunotherapy of cancer

Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S.
PMID: 32114499
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000268.

Immunotherapy has moved to the forefront of cancer treatment, illustrated by the accelerating pace of novel therapy approvals. In this complex environment, scientists rely on cutting edge conferences to stay informed. The Immunotherapy of Cancer (ITOC) conference was established...

Cite
Pinto C, Bergmann M, Briukhovetska D, et al. Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report. J Immunother Cancer. 2020;8(1)doi: 10.1136/jitc-2019-000268.
Pinto, C., Bergmann, M., Briukhovetska, D., Nuessler, V., Sznol, M., von Bergwelt-Baildon, M., & Kobold, S. (2020). Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report. Journal for immunotherapy of cancer, 8(1), . https://doi.org/10.1136/jitc-2019-000268
Pinto, Catarina, et al. "Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report." Journal for immunotherapy of cancer vol. 8,1 (2020). doi: https://doi.org/10.1136/jitc-2019-000268
Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S. Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report. J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000268. PMID: 32114499; PMCID: PMC7057436.
Copy Download .nbib Format: NLM
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.

Targeted oncology

Paliard X, Rixe O.
PMID: 31595386
Target Oncol. 2019 Dec;14(6):631-637. doi: 10.1007/s11523-019-00678-w.

The clinical development of cancer drugs is rapidly moving from empirical "one drug fits all" or development-by-tumor-type approaches towards more personalized treatment models. A deeper understanding of cancer and the immune system, novel technologies, and powerful analytics have fueled...

Cite
Paliard X, Rixe O. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials. Target Oncol. 2019;14(6):631-637doi: 10.1007/s11523-019-00678-w.
Paliard, X., & Rixe, O. (2019). Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials. Targeted oncology, 14(6), 631-637. https://doi.org/10.1007/s11523-019-00678-w
Paliard, Xavier, and Rixe, Olivier. "Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials." Targeted oncology vol. 14,6 (2019): 631-637. doi: https://doi.org/10.1007/s11523-019-00678-w
Paliard X, Rixe O. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials. Target Oncol. 2019 Dec;14(6):631-637. doi: 10.1007/s11523-019-00678-w. PMID: 31595386; PMCID: PMC6875515.
Copy Download .nbib Format: NLM
Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents.

The Gulf journal of oncology

Abu-Shawer O, Bushnaq T, Abu-Shawer M.
PMID: 30956199
Gulf J Oncolog. 2019 Jan;1(29):76-82.

After several years of discouraging results, immunotherapy finally becomes a powerful, clinically valid and approved treatment for numerous types of cancer. Immunotherapy involves treatment approaches that work in various ways; some boost the body's immune system while others help...

Cite
Abu-Shawer O, Bushnaq T, Abu-Shawer M. Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents. Gulf J Oncolog. 2019;1(29):76-82
Abu-Shawer, O., Bushnaq, T., & Abu-Shawer, M. (2019). Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents. The Gulf journal of oncology, 1(29), 76-82.
Abu-Shawer, Osama, et al. "Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents." The Gulf journal of oncology vol. 1,29 (2019): 76-82.
Abu-Shawer O, Bushnaq T, Abu-Shawer M. Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents. Gulf J Oncolog. 2019 Jan;1(29):76-82. PMID: 30956199.
Copy Download .nbib Format: NLM
Preface.

Anticancer research

Fukushima T.
PMID: 31366564
Anticancer Res. 2019 Aug;39(8):NP.

No abstract available.

Cite
Fukushima T. Preface. Anticancer Res. 2019;39(8):NP
Fukushima, T. (2019). Preface. Anticancer research, 39(8), NP.
Fukushima, Takeo. "Preface." Anticancer research vol. 39,8 (2019): NP.
Fukushima T. Preface. Anticancer Res. 2019 Aug;39(8):NP. PMID: 31366564.
Copy Download .nbib Format: NLM
[No title available]

ESMO open

Lambertini M.
PMID: 32376765
ESMO Open. 2020 May;4:e000795. doi: 10.1136/esmoopen-2020-000795. Epub 2020 May 06.

Click here to listen to the Podcast.

Cite
Lambertini M. . ESMO Open. 2020;4:e000795doi: 10.1136/esmoopen-2020-000795.
Lambertini, M. (2020). . ESMO open, 4e000795. https://doi.org/10.1136/esmoopen-2020-000795
Lambertini, Matteo. "." ESMO open vol. 4 (2020): e000795. doi: https://doi.org/10.1136/esmoopen-2020-000795
Lambertini M. . ESMO Open. 2020 May;4:e000795. doi: 10.1136/esmoopen-2020-000795. Epub 2020 May 06. PMID: 32376765; PMCID: PMC7326248.
Copy Download .nbib Format: NLM
How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?.

Current opinion in oncology

Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A.
PMID: 31335831
Curr Opin Oncol. 2019 Sep;31(5):420-423. doi: 10.1097/CCO.0000000000000563.

PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICIs) are rapidly changing practice across different tumor settings. With this article, we reflect on how to assimilate the tsunami of ICIs data into clinical practice.RECENT FINDINGS: A tremendous increase on approvals, number...

Cite
Castelo-Branco L, Aspeslagh S, Kotecki N, et al. How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?. Curr Opin Oncol. 2019;31(5):420-423doi: 10.1097/CCO.0000000000000563.
Castelo-Branco, L., Aspeslagh, S., Kotecki, N., & Awada, A. (2019). How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?. Current opinion in oncology, 31(5), 420-423. https://doi.org/10.1097/CCO.0000000000000563
Castelo-Branco, Luís, et al. "How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?." Current opinion in oncology vol. 31,5 (2019): 420-423. doi: https://doi.org/10.1097/CCO.0000000000000563
Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A. How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?. Curr Opin Oncol. 2019 Sep;31(5):420-423. doi: 10.1097/CCO.0000000000000563. PMID: 31335831.
Copy Download .nbib Format: NLM
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga.

Trends in cancer

Catalano I, Grassi E, Bertotti A, Trusolino L.
PMID: 31813455
Trends Cancer. 2019 Dec;5(12):779-788. doi: 10.1016/j.trecan.2019.10.006. Epub 2019 Nov 06.

Immunotherapy with immune checkpoint inhibitors is an approved treatment option for a subpopulation of patients with colorectal cancers that display microsatellite instability. However, not all individuals within this subgroup respond to immunotherapy, and molecular biomarkers for effective patient stratification...

Cite
Catalano I, Grassi E, Bertotti A, et al. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends Cancer. 2019;5(12):779-788doi: 10.1016/j.trecan.2019.10.006.
Catalano, I., Grassi, E., Bertotti, A., & Trusolino, L. (2019). Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends in cancer, 5(12), 779-788. https://doi.org/10.1016/j.trecan.2019.10.006
Catalano, Irene, et al. "Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga." Trends in cancer vol. 5,12 (2019): 779-788. doi: https://doi.org/10.1016/j.trecan.2019.10.006
Catalano I, Grassi E, Bertotti A, Trusolino L. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends Cancer. 2019 Dec;5(12):779-788. doi: 10.1016/j.trecan.2019.10.006. Epub 2019 Nov 06. PMID: 31813455.
Copy Download .nbib Format: NLM
Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy.

Journal for immunotherapy of cancer

Zhang Y, Yao Y, Chen P, Liu Y, Zhang H, Liu H, Liu Y, Xu H, Tian X, Wang Z, Chu P, Zhao D, Liu H, Zhang C, Chen S, Zhao Y, Liu C, Yang Y.
PMID: 33109630
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001247.

BACKGROUND: Checkpoint targets play a key role in tumor-mediated immune escape and therefore are critical for cancer immunotherapy. Unfortunately, there is a lack of bioinformatics resource that compile all the checkpoint targets for translational research and drug discovery in...

Cite
Zhang Y, Yao Y, Chen P, et al. Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy. J Immunother Cancer. 2020;8(2)doi: 10.1136/jitc-2020-001247.
Zhang, Y., Yao, Y., Chen, P., Liu, Y., Zhang, H., Liu, H., Liu, Y., Xu, H., Tian, X., Wang, Z., Chu, P., Zhao, D., Liu, H., Zhang, C., Chen, S., Zhao, Y., Liu, C., & Yang, Y. (2020). Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy. Journal for immunotherapy of cancer, 8(2), . https://doi.org/10.1136/jitc-2020-001247
Zhang, Yixiao, et al. "Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy." Journal for immunotherapy of cancer vol. 8,2 (2020). doi: https://doi.org/10.1136/jitc-2020-001247
Zhang Y, Yao Y, Chen P, Liu Y, Zhang H, Liu H, Liu Y, Xu H, Tian X, Wang Z, Chu P, Zhao D, Liu H, Zhang C, Chen S, Zhao Y, Liu C, Yang Y. Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy. J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001247. PMID: 33109630; PMCID: PMC7592241.
Copy Download .nbib Format: NLM
Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives.

Cancer biotherapy & radiopharmaceuticals

Sardaro A, Ferrari C, Carbonara R, Altini C, Lavelli V, Rubini G.
PMID: 32551915
Cancer Biother Radiopharm. 2021 Mar;36(2):123-132. doi: 10.1089/cbr.2020.3643. Epub 2020 Jun 16.

No abstract available.

Cite
Sardaro A, Ferrari C, Carbonara R, et al. Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. Cancer Biother Radiopharm. 2020;36(2):123-132doi: 10.1089/cbr.2020.3643.
Sardaro, A., Ferrari, C., Carbonara, R., Altini, C., Lavelli, V., & Rubini, G. (2021). Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. Cancer biotherapy & radiopharmaceuticals, 36(2), 123-132. https://doi.org/10.1089/cbr.2020.3643
Sardaro, Angela, et al. "Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives." Cancer biotherapy & radiopharmaceuticals vol. 36,2 (2021): 123-132. doi: https://doi.org/10.1089/cbr.2020.3643
Sardaro A, Ferrari C, Carbonara R, Altini C, Lavelli V, Rubini G. Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. Cancer Biother Radiopharm. 2021 Mar;36(2):123-132. doi: 10.1089/cbr.2020.3643. Epub 2020 Jun 16. PMID: 32551915.
Copy Download .nbib Format: NLM
Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic.

Cancer

Printz C.
PMID: 33460046
Cancer. 2020 Oct 15;126(20):4443-4444. doi: 10.1002/cncr.33228.

No abstract available.

Cite
Printz C. Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic. Cancer. 2020;126(20):4443-4444doi: 10.1002/cncr.33228.
Printz, C. (2020). Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic. Cancer, 126(20), 4443-4444. https://doi.org/10.1002/cncr.33228
Printz, Carrie. "Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic." Cancer vol. 126,20 (2020): 4443-4444. doi: https://doi.org/10.1002/cncr.33228
Printz C. Experts discuss cancer care and research in the age of COVID-19: Findings presented at the American Association for Cancer Research's virtual meeting could shift clinicians' thinking about immunotherapy and point to encouraging changes in the way that clinical trials are being conducted during the pandemic. Cancer. 2020 Oct 15;126(20):4443-4444. doi: 10.1002/cncr.33228. PMID: 33460046.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 32 entries